Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics


Coherus BioSciences, Inc. (CHRS): $17.52

0.46 (+2.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CHRS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

CHRS POWR Grades


  • CHRS scores best on the Value dimension, with a Value rank ahead of 95.18% of US stocks.
  • The strongest trend for CHRS is in Momentum, which has been heading down over the past 48 weeks.
  • CHRS ranks lowest in Growth; there it ranks in the 6th percentile.

CHRS Stock Summary

  • Of note is the ratio of Coherus BioSciences Inc's sales and general administrative expense to its total operating expenses; just 15.08% of US stocks have a lower such ratio.
  • Over the past twelve months, CHRS has reported earnings growth of -168.98%, putting it ahead of just 12.33% of US stocks in our set.
  • Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at -19.03%, a number that bests only 12.94% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CHRS, based on their financial statements, market capitalization, and price volatility, are EIGR, MCRB, SVRA, CTMX, and BLCM.
  • CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to www.coherus.com.

CHRS Valuation Summary

  • CHRS's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
  • Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
  • Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.

Below are key valuation metrics over time for CHRS.

Stock Date P/S P/B P/E EV/EBIT
CHRS 2021-08-31 3.1 7.8 -7.4 -9.3
CHRS 2021-08-30 3.1 7.8 -7.3 -9.2
CHRS 2021-08-27 3.1 7.7 -7.3 -9.1
CHRS 2021-08-26 3.1 7.7 -7.3 -9.2
CHRS 2021-08-25 3.0 7.6 -7.2 -9.0
CHRS 2021-08-24 3.0 7.5 -7.1 -8.9

CHRS Growth Metrics

  • Its year over year revenue growth rate is now at 1.73%.
  • The 2 year cash and equivalents growth rate now stands at 135.47%.
  • Its 2 year net cashflow from operations growth rate is now at 161.53%.
Over the past 33 months, CHRS's revenue has gone up $394,647,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 394.647 81.656 -165.206
2021-03-31 442.678 142.035 -76.275
2020-12-31 475.824 154.145 132.244
2020-09-30 489.261 138.731 161.763
2020-06-30 487.394 146.329 180.873
2020-03-31 435.153 98.815 145.409

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CHRS has a Quality Grade of B, ranking ahead of 81.32% of graded US stocks.
  • CHRS's asset turnover comes in at 0.513 -- ranking 81st of 677 Pharmaceutical Products stocks.
  • CPRX, XTNT, and ONCT are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.513 0.886 -0.228
2021-03-31 0.572 0.913 -0.075
2020-12-31 0.664 0.921 0.250
2020-09-30 0.803 0.931 0.332
2020-06-30 0.995 0.936 0.477
2020-03-31 1.206 0.950 0.576

CHRS Price Target

For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.71 Average Broker Recommendation 1.57 (Moderate Buy)

CHRS Stock Price Chart Interactive Chart >

Price chart for CHRS

CHRS Price/Volume Stats

Current price $17.52 52-week high $22.22
Prev. close $17.06 52-week low $12.21
Day low $16.90 Volume 495,500
Day high $17.59 Avg. volume 973,575
50-day MA $14.63 Dividend yield N/A
200-day MA $15.40 Market Cap 1.34B

Coherus BioSciences, Inc. (CHRS) Company Bio


Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.


CHRS Latest News Stream


Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream


Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial. Related: Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial. The trial is evaluating toripalimab in combination with chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC). The results were presented at the European Society for Medical Oncology (ESMO21) Virtual Con

Yahoo | September 17, 2021

Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in 2022 – SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,

Yahoo | September 16, 2021

Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine

- Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma -REDWOOD CITY, Calif., and SHANGHAI, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced publication of a cover article in the September issue of Nature Medicine featuring clinical data from the pivotal study “JUPITER-02”, a randomi

Yahoo | September 15, 2021

Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

SHANGHAI, China and REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as the first-line treatment of advanced squamous or non-squamous non-s

Yahoo | September 14, 2021

Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-smal

Yahoo | September 14, 2021

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo 13.40%
3-mo 13.69%
6-mo 20.58%
1-year -2.61%
3-year 5.54%
5-year -41.60%
YTD 0.81%
2020 -3.47%
2019 98.95%
2018 2.84%
2017 -68.74%
2016 22.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9569 seconds.